-
Mashup Score: 1Pembrolizumab/MK-1084 Combo Is the Focus of Phase 3 Trial in KRAS G12C+ Metastatic NSCLC - 22 day(s) ago
MK-1084 previously demonstrated manageable safety and preliminary activity in non–small cell lung cancer harboring KRAS G12C mutations as part of a phase 1 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 24 day(s) ago
The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 40ESMO Guidelines: Real World Cases - Webinar Series: Non-Oncogene-Addicted Metastatic Non-small-cell Lung Cancer (NSCLC) 2024 - 26 day(s) ago
ESMO Guidelines: Real World Cases – Webinar Series: Non-Oncogene-Addicted Metastatic Non-small-cell Lung Cancer (NSCLC) 2024Chair: Antonio PassaroSpeakers: Hongcheng Zhu, Solange Peters, Jaafar Bennouna
Source: oncologypro.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16NSCLC Clinical Case Simulations for Practicing Oncologists - 29 day(s) ago
Welcome to our interactive training module. Please select from below to
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The phase 3 KEYLYNK-006 trial did not meet the primary end points of progression-free and overall survival in patients with metastatic nonsquamous non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2About the Continued Evaluation of MK-1084 for NSCLC and More - 1 month(s) ago
Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC - 1 month(s) ago
The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment - 1 month(s) ago
Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
A phase 3 trial has been launched assessing frontline MK-1084 plus pembrolizumab in KRASG12C-mutated PD-L1 #NSCLC. https://t.co/1K83dULJ6J